Excessive buccal saliva in patients with Parkinson’s disease of the French COPARK cohort
J Neural Transm. 2020-09-02; 127(12): 1607-1617
DOI: 10.1007/s00702-020-02249-0
Read on PubMed
Rascol O(1), Negre-Pages L(2)(3), Damier P(4), Delval A(5), Derkinderen P(4),Destée A(5), Fabbri M(6), Meissner WG(7)(8)(9), Rachdi A(10), Tison F(7)(8), Perez-Lloret S(11)(12)(13); COPARK Study Group.
Author information:
(1)Centre D’Investigation Clinique CIC 1436, Services de Pharmacologie Clinique
Et Neurosciences, NS-Park/FCRIN Network, NeuroToul COEN Center, Université de
Toulouse UPS, CHU de Toulouse, INSERM Toulouse, 37 Allées Jules Guesde, 31000,
Toulouse, France. .
(2)LN Pharma, Toulouse, France.
(3)Unité de Recherche Clinique Et Epidémiologie, Département D’Information
Médicale, Hôpital La Colombière, Montpellier, France.
(4)Department of Neurology, NS-Park/FCRIN Network, Université de Nantes, CHU de
Nantes, INSERM; CIC 1413, Nantes, France.
(5)Department of Neurology, U 837, NS-Park/FCRIN Network, Université de Lille,
CHU de Lille, INSERM, Lille, France.
(6)Department of Neuroscience, University of Turin, Torino, Italy.
(7)Service de Neurologie, NS-Park/FCRIN Network, CHU de Bordeaux, 33000,
Bordeaux, France.
(8)Institut Des Maladies Neurodégénératives, CNRS UMR 5293, Univ. de Bordeaux,
33000, Bordeaux, France.
(9)Dept. Medicine, University of Otago, Christchurch, and New Zealand Brain
Research Institute, Christchurch, New Zealand.
(10)Centre D’Investigation Clinique CIC 1436, Services de Pharmacologie Clinique
Et Neurosciences, NS-Park/FCRIN Network, NeuroToul COEN Center, Université de
Toulouse UPS, CHU de Toulouse, INSERM Toulouse, 37 Allées Jules Guesde, 31000,
Toulouse, France.
(11)Biomedical Research Center, Interamerican Open University (CAECIHS-UAI),
National Research Council (CONICET), Buenos Aires, Argentina.
(12)Department of Physiology, School of Medicine, University of Buenos Aires
(UBA), Buenos Aires, Argentina.
(13)Faculty of Medical Sciences, Pontificia Universidad Católica Argentina (UCA),
Buenos Aires, Argentina.
Erratum in
J Neural Transm (Vienna). 2020 Oct 21;:.
We describe excessive buccal saliva (EBS) prevalence in patients with Parkinson’s
Disease (PD) and controls of the COPARK study, its changes between “ON” and OFF”
conditions and over time, its impact on Health-related Quality of life (HRQoL),
and factors associated with this condition. We studied 671 ambulatory PD patients
and 177 age/sex-matched controls. We defined “sialorrhea” as UPDRS item #6
(salivation) = 1 or 2; and “drooling” as item #6 = 3 or 4. SCOPA-Aut drooling
score (item #2) was also available in a subset (45%) of the cohort. HRQoL was
assessed by the PDQ-39 and SF-36 scales. Twenty-four months’ follow-up data were
available in 401/671 patients. EBS as assessed by UPDRS was present in 38% of PD
patients in the “ON” condition (“Sialorrhea”: 35%; “drooling”: 3%). There were
also more PD patients reporting “drooling” than controls according to the
SCOPA-Aut (49% vs 19%, p